AR098716A1 - Formas de dosificación farmacéuticas - Google Patents
Formas de dosificación farmacéuticasInfo
- Publication number
- AR098716A1 AR098716A1 ARP140104615A ARP140104615A AR098716A1 AR 098716 A1 AR098716 A1 AR 098716A1 AR P140104615 A ARP140104615 A AR P140104615A AR P140104615 A ARP140104615 A AR P140104615A AR 098716 A1 AR098716 A1 AR 098716A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage forms
- pharmaceutical dosage
- weight
- piperazin
- phenylamino
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 239000002775 capsule Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- -1 2,6-dichloro-3,5-dimethoxy-phenyl Chemical group 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formas sólidas de dosificación farmacéutica que comprenden 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea o cualquier sal farmacéuticamente aceptable del mismo. Procesos de elaboración de dichas formas sólidas de dosificación farmacéutica. Reivindicación 1: Una cápsula para administración oral que comprende (a) el fármaco 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea o cualquier sal farmacéuticamente aceptable del mismo, (b) uno o más aglutinantes, y (c) uno o más desintegrantes. Reivindicación 26: Una cápsula para administración oral que comprende cualquiera de las reivindicaciones 1 a 7, 19 ó 25 que comprende: (a) entre 3 y 40% por peso del fármaco 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea en su forma de base libre presente como sal de mono-fosfato, (b) entre 0.5 y 5% por peso de hidroxipropilmetilcelulosa, y (c) entre 1 y 4% por peso de polivinilpirrolidona entrecruzada, con base en el peso total del contenido de la cápsula.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915606P | 2013-12-13 | 2013-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098716A1 true AR098716A1 (es) | 2016-06-08 |
Family
ID=52146563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104615A AR098716A1 (es) | 2013-12-13 | 2014-12-11 | Formas de dosificación farmacéuticas |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10278969B2 (es) |
| EP (2) | EP3079667B1 (es) |
| JP (2) | JP6522619B2 (es) |
| KR (1) | KR102349893B1 (es) |
| CN (2) | CN116942629A (es) |
| AR (1) | AR098716A1 (es) |
| AU (1) | AU2014362999B2 (es) |
| CA (1) | CA2930055C (es) |
| CL (1) | CL2016001436A1 (es) |
| CY (1) | CY1122063T1 (es) |
| DK (1) | DK3079667T3 (es) |
| EA (1) | EA036288B1 (es) |
| EC (1) | ECSP16060194A (es) |
| ES (1) | ES2745983T3 (es) |
| HK (1) | HK1223833A1 (es) |
| HR (1) | HRP20191691T1 (es) |
| HU (1) | HUE045156T2 (es) |
| IL (1) | IL245705B (es) |
| LT (1) | LT3079667T (es) |
| MA (1) | MA39175A1 (es) |
| MX (1) | MX2016007652A (es) |
| MY (1) | MY194303A (es) |
| NZ (2) | NZ760002A (es) |
| PE (1) | PE20160851A1 (es) |
| PH (1) | PH12016501039A1 (es) |
| PL (1) | PL3079667T3 (es) |
| PT (1) | PT3079667T (es) |
| RS (1) | RS59270B1 (es) |
| SG (1) | SG10202104627UA (es) |
| SI (1) | SI3079667T1 (es) |
| TN (1) | TN2016000207A1 (es) |
| TW (2) | TWI800759B (es) |
| WO (1) | WO2015087283A1 (es) |
| ZA (1) | ZA201603064B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3079667B1 (en) | 2013-12-13 | 2019-06-26 | Novartis AG | Pharmaceutical dosage forms |
| MA41611A (fr) * | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| IL303500A (en) * | 2020-12-18 | 2023-08-01 | Qed Therapeutics Inc | Methods for treating achondroplasia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| WO2007071752A2 (en) | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| FR2910813B1 (fr) * | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| CA2840620A1 (en) | 2011-07-01 | 2013-01-10 | Novartis Ag | Combination therapy |
| CA2917667A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| EP3079667B1 (en) | 2013-12-13 | 2019-06-26 | Novartis AG | Pharmaceutical dosage forms |
| EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
| JP2018509448A (ja) | 2015-03-25 | 2018-04-05 | ノバルティス アーゲー | 組合せ医薬 |
| AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
-
2014
- 2014-12-11 EP EP14819084.6A patent/EP3079667B1/en active Active
- 2014-12-11 SI SI201431315T patent/SI3079667T1/sl unknown
- 2014-12-11 TN TN2016000207A patent/TN2016000207A1/en unknown
- 2014-12-11 SG SG10202104627UA patent/SG10202104627UA/en unknown
- 2014-12-11 US US15/102,378 patent/US10278969B2/en active Active
- 2014-12-11 NZ NZ760002A patent/NZ760002A/en unknown
- 2014-12-11 PE PE2016000773A patent/PE20160851A1/es unknown
- 2014-12-11 ES ES14819084T patent/ES2745983T3/es active Active
- 2014-12-11 CN CN202310950714.8A patent/CN116942629A/zh active Pending
- 2014-12-11 PT PT148190846T patent/PT3079667T/pt unknown
- 2014-12-11 MX MX2016007652A patent/MX2016007652A/es active IP Right Grant
- 2014-12-11 AU AU2014362999A patent/AU2014362999B2/en active Active
- 2014-12-11 EP EP19181217.1A patent/EP3597179B1/en active Active
- 2014-12-11 LT LTEP14819084.6T patent/LT3079667T/lt unknown
- 2014-12-11 CA CA2930055A patent/CA2930055C/en active Active
- 2014-12-11 DK DK14819084.6T patent/DK3079667T3/da active
- 2014-12-11 AR ARP140104615A patent/AR098716A1/es not_active Application Discontinuation
- 2014-12-11 NZ NZ719865A patent/NZ719865A/en unknown
- 2014-12-11 CN CN201480067964.6A patent/CN105813635A/zh active Pending
- 2014-12-11 MY MYPI2016701712A patent/MY194303A/en unknown
- 2014-12-11 KR KR1020167015239A patent/KR102349893B1/ko active IP Right Grant
- 2014-12-11 PL PL14819084T patent/PL3079667T3/pl unknown
- 2014-12-11 WO PCT/IB2014/066820 patent/WO2015087283A1/en active Application Filing
- 2014-12-11 MA MA39175A patent/MA39175A1/fr unknown
- 2014-12-11 RS RSP20191178 patent/RS59270B1/sr unknown
- 2014-12-11 HU HUE14819084A patent/HUE045156T2/hu unknown
- 2014-12-11 EA EA201691231A patent/EA036288B1/ru unknown
- 2014-12-11 JP JP2016538536A patent/JP6522619B2/ja active Active
- 2014-12-12 TW TW109136485A patent/TWI800759B/zh active
- 2014-12-12 TW TW103143546A patent/TWI721938B/zh active
-
2016
- 2016-05-06 ZA ZA2016/03064A patent/ZA201603064B/en unknown
- 2016-05-18 IL IL245705A patent/IL245705B/en active IP Right Grant
- 2016-06-01 PH PH12016501039A patent/PH12016501039A1/en unknown
- 2016-06-10 CL CL2016001436A patent/CL2016001436A1/es unknown
- 2016-07-13 EC ECIEPI201660194A patent/ECSP16060194A/es unknown
- 2016-10-20 HK HK16112100.4A patent/HK1223833A1/zh unknown
-
2019
- 2019-03-26 US US16/364,727 patent/US11160804B2/en active Active
- 2019-04-23 JP JP2019082147A patent/JP6804585B2/ja active Active
- 2019-09-18 HR HRP20191691TT patent/HRP20191691T1/hr unknown
- 2019-09-23 CY CY20191100999T patent/CY1122063T1/el unknown
-
2021
- 2021-09-29 US US17/489,382 patent/US20220265651A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| CL2015003117A1 (es) | Modificaciones en la estructura cristalina | |
| DOP2016000150A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| JP2014141525A5 (es) | ||
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| TR201908596T4 (tr) | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| PE20141012A1 (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion | |
| CL2016001094A1 (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
| AR098716A1 (es) | Formas de dosificación farmacéuticas | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| AR091886A1 (es) | Dispositivo dispensador | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| BR112015028890A2 (pt) | derivados de piridona para o tratamento de infecções virais e outras doenças | |
| AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
| CL2016000183A1 (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| MX2015012542A (es) | Partículas de resinato de fenilefrina y su uso en formulaciones para productos farmacéuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |